youtube_live
Q3 2026 earnings • in 1 day
See detailschevron_right
PRGO:NYSE
Perrigo Company PLC
$15.75
arrow_downward
-0.28%(-0.045) 1D
$15.75
0.00% (0.00)
bedtimeAfter hours
Closed: Nov 2, 4:00:04 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for PRGO...
Open
$15.95
High
$16.05
Low
$15.64
Mkt. cap
2.19B
Avg. vol.
2.63M
Volume
2.01M
Dividend
7.37%
Quarterly dividend
$0.29
Ex-dividend date
Aug 28, 2026
52-wk high
$20.65
52-wk low
$9.22
EPS
-$12.59
Beta
0.67
Shares outstanding
138.77M
No. of employees
8K
Open
$15.95
High
$16.05
Low
$15.64
Mkt. cap
2.19B
Avg. vol.
2.63M
Volume
2.01M
Dividend
7.37%
Quarterly dividend
$0.29
Ex-dividend date
Aug 28, 2026
52-wk high
$20.65
52-wk low
$9.22
EPS
-$12.59
Beta
0.67
Shares outstanding
138.77M
No. of employees
8K
News stories
From web sources and news partners
St. Albans Messenger
·
15 hours ago
Perrigo’s infant formula business bought by MeridianMade; Georgia facility to be evaluated
FoodBev Media
·
23 hours ago
Perrigo to sell infant formula business to MeridianMade for up to $175m
Profile
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters in Grand Rapids, Michigan, within Michigan State University's Grand Rapids Innovation Park.
Perrigo engages in the acquisition, manufacture, and sale of consumer healthcare products, generic prescription drugs, and active pharmaceutical ingredients, primarily in the United States, from its base in Ireland. On 21 December 2018, Perrigo suffered its biggest one-day share price fall in its history after the Irish Revenue Commissioners issued a tax claim against Perrigo that equated to half of its market value. Wikipedia
About Perrigo Company PLC
CEOMurray S. Kessler
Employees8.1K
Founded1887
Headquarters-
SectorPharmaceutical industry
Websiteperrigo.com
Analyst ratings
Based on 2 analysts giving stock ratings to PRGO in the past 3 months
Buy
Buy
1
Hold
1
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for PRGO in the last 3 months.
Highest
Current $15.75
$19.00 (+20.63%)
Average
$17.00 (+7.94%)
Lowest
$15.00 (-4.76%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Susan Anderson Canaccord Genuity | Buy | Maintained | $19.00 | +20.6% | 10/30/2026 |
Chris Schott J.P. Morgan | Hold | Maintained | $15.00 | -4.8% | 10/21/2026 |
Christine Dooley Argus Research | Hold | Maintained | - | - | 05/19/2026 |
Keith Devas Jefferies | Hold | Maintained | $23.00 | +46% | 10/27/2025 |
Next call in 28:36:06
Wed, Nov 4, 8:30 AM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / $0.53
Revenue / Est. (USD)
- / 995.90M
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 1.04B | 1.11B | 969.20M | 1.02B |
Cost of goods sold | 666.20M | 747.40M | 643.70M | 708.90M |
Cost of revenue | 666.20M | 747.40M | 643.70M | 708.90M |
Research and development expenses | 24.90M | 21.80M | 24.60M | 23.70M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 245.70M | 255.60M | 267.30M | 251.20M |
Operating expense | 283.50M | 249.00M | 291.90M | 274.60M |
Total operating expenses | 949.70M | 996.40M | 935.60M | 983.50M |
Operating income | 93.60M | 113.20M | 33.60M | 39.30M |
Other non operating income | 300.00K | -10.70M | 3.70M | 10.10M |
EBT including unusual items | 22.40M | -1.33B | -408.60M | 105.50M |
EBT excluding unusual items | 43.20M | 68.70M | -1.30M | -8.50M |
Income tax expense | 9.70M | 82.90M | -18.70M | 16.90M |
Effective tax rate | 43.30% | -6.23% | 4.58% | 16.02% |
Other operating expenses | 12.90M | -28.40M | - | -300.00K |
Net income | 7.50M | -1.42B | -398.60M | 74.50M |
Net profit margin | 0.72% | -127.80% | -41.13% | 7.28% |
Earnings per share | 0.80 | 0.77 | 0.43 | 0.50 |
Interest and investment income | - | - | - | - |
Interest expense | -50.10M | -52.80M | -49.00M | -47.00M |
Net interest expenses | -50.10M | -52.80M | -49.00M | -47.00M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 179.00M | 199.10M | 116.90M | 116.20M |
Gain or loss from assets sale | - | - | - | -129.50M |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events